ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADPT Adaptive Biotechnologies Corporation

3.63
-0.09 (-2.42%)
May 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,573,104
Bid Price 2.50
Ask Price 4.70
News (1)
Day High 3.76

Low
2.28

52 Week Range

High
9.0799

Day Low 3.57
Company Name Stock Ticker Symbol Market Type
Adaptive Biotechnologies Corporation ADPT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -2.42% 3.63 00:00:01
Open Price Low Price High Price Close Price Prev Close
3.75 3.57 3.76 3.61 3.72
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,177 1,573,104 $ 3.66 $ 5,756,306 - 2.28 - 9.0799
Last Trade Time Type Quantity Stock Price Currency
19:38:07 1 $ 3.6284 USD

Adaptive Biotechnologies Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
522.33M 145.09M - 170.28M -225.25M -1.55 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Adaptive Biotechnologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ADPT Message Board. Create One! See More Posts on ADPT Message Board See More Message Board Posts

Historical ADPT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.574.203.4553.801,761,0600.061.68%
1 Month2.314.202.283.071,642,6371.3257.14%
3 Months3.874.3452.283.131,723,261-0.24-6.20%
6 Months4.065.492.283.721,557,346-0.43-10.59%
1 Year6.239.07992.284.741,442,056-2.60-41.73%
3 Years34.0243.39682.2810.601,170,260-30.39-89.33%
5 Years39.0171.252.2820.321,073,323-35.38-90.69%

Adaptive Biotechnologies Description

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.